Why it was recalled
Lack of Assurance of Sterility
Product description
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Lot numbers, UPCs & expiration codes
Lot Number 01-27-2026@14S.5
Where it was sold
OR
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-0471-2026
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- Mar 6, 2026
- FDA report date
- Apr 22, 2026
- Quantity
- 91 vials
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- PAYLESS COMPOUNDERS, LLC
Original FDA data
Every field from FDA enforcement report D-0471-2026, exactly as published.
Show all FDA fields
- City
- Beaverton
- State
- OR
- Status
- Ongoing
- Country
- United States
- Event ID
- 98646
- Address
- 8505 Sw Creekside Pl Ste 110
- Code information
- Lot Number 01-27-2026@14S.5
- Postal code
- 97008-7128
- Report date
- Apr 22, 2026
- Product type
- Drugs
- Recall number
- D-0471-2026
- Classification
- Class II
- Recalling firm
- PAYLESS COMPOUNDERS, LLC
- Product quantity
- 91 vials
- Reason for recall
- Lack of Assurance of Sterility
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
- Distribution pattern
- OR
- Recall initiation date
- Mar 6, 2026
- Initial firm notification
- Letter
- Center classification date
- Apr 13, 2026